GO
Loading...

Onyx Pharmaceuticals Inc

More

  • Onyx Hires New CEO--But Here's What You Won't Find In PR Wednesday, 27 Feb 2008 | 3:28 PM ET

    Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.

  • Black Tuesday for Onyx Tuesday, 19 Feb 2008 | 12:27 PM ET

    Almost exactly one year since Onyx Pharmaceuticals announced positive results of its drug Nexavar for liver cancer and the stock doubled in one day, the biopharmaceutical company is providing an example of the ups and downs of drug development and biotech investing.

  • Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.

  • Lightning Round: Citi, Raytheon, SanDisk and More Thursday, 3 Jan 2008 | 11:07 AM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.

  • Lightning Round: DryShips, Wynn, Annaly and More Thursday, 15 Nov 2007 | 10:52 AM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Back To Biotech: Risk & Reward Wednesday, 14 Nov 2007 | 11:06 AM ET

    In 1990, Amgen was the risky-but-profitable biotech of choice. Today, its stand-in is Onyx Pharmaceuticals.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Winners & Losers: Financials Get Pounded Wednesday, 7 Nov 2007 | 6:59 PM ET

    The financial sector continues to get pounded. General Motors reported a significant third-quarter loss, but there is a glimmer of hope in the pharmaceutical industry. 

  • Pharma Stock Picks From a Five-Star Fund Manager Monday, 22 Oct 2007 | 1:05 PM ET

    To a five-star fund manager, it's not how big the stars are, but how brightly they're shining.  In the pharmaceutical field, Kris Jenner of T. Rowe Price finds brightness at both ends of the size spectrum.

  • Biogen Idec: First Of A Biotech Buying Binge? Monday, 15 Oct 2007 | 12:52 PM ET

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • Glaxo Buys into Synta, Investors Sell Wednesday, 10 Oct 2007 | 1:08 PM ET

    Melanoma -- a type of skin cancer -- is the most common form of cancer. It can spread very quickly and the prognosis often is not good. The American Cancer Society estimates that nearly 60,000 new cases of melanoma will be diagnosed this year and more than 8,000 patients will die. You can find out more about it on the ACS's website.

  • Stocks Close Near Lows, Led by Financials, Utilities Monday, 27 Aug 2007 | 4:13 PM ET
    Traders at SIG Specialists trading post on the floor of the New York Stock Exchange talk among themselves shortly after the opening bell Monday, April 18, 2005, in New York.  Stocks regained some stability Monday following a three-day selloff as strong first-quarter earnings and a pair of merger announcements lent some support to a market battered by worries about economic growth.  (AP Photo/Kathy Willens)

    Stocks closed broadly lower at the end of a light-volume trading session as continued weakness in financial stocks brought down the major indexes. The Dow fell 56 points, closing near the lows of the trading session, while the S&P 500 and Nasdaq Composite ended with respective losses of 0.9% and 0.6%, respectively.

  • Bayer Fast Tracks Nexavar After Positive Drug Trials Monday, 27 Aug 2007 | 5:45 AM ET

    Bayer and Onyx Pharmaceuticals said they were stopping a late clinical liver cancer trial with Nexavar in the Asia-Pacific region so patients can get the drug sooner after encouraging results.

  • It's Time for the Lightning Round! Friday, 6 Jul 2007 | 6:58 PM ET

    Omniture, Sears, AG Edwards and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks closed with modest gains as investors shrugged off sharp declines in China and higher energy prices amid continued mergers and acquisitions activity. "Right now we're in a glass-half-full type of mood," said Al Goldman, chief market strategist at A.G. Edwards. "The market just doesn't seem to go down."

  • Hot Stocks: ASCO's Winners and Losers Monday, 4 Jun 2007 | 4:27 PM ET

    A roundup of the most actively traded biotech and pharma stocks following the annual American Society of Clinical Oncology conference in Chicago.

  • Onyx Pharamaceuticals shares rose sharply after its partner Bayer said results of a Phase 3 study showed that Nexavar significantly extended overall survival in patients with liver cancer by 44%.

  • Selling Hope: The Cost Of Curing Cancer Monday, 4 Jun 2007 | 1:24 PM ET

    The American Society of clinical Oncology is underway in Chicago and the high profile, annual cancer conference is producing its usual combination of scientific and financial excitement.

  • CNBC's Domm: Today's Agenda in the Markets Monday, 4 Jun 2007 | 8:43 AM ET

    Stocks are weaker ahead of the open despite a round of Monday morning mergers. Asian markets were higher, ignoring another selloff in China overnight, and European markets are lower.

  • Game Plan for the Week of June 4 Friday, 1 Jun 2007 | 6:57 PM ET

    Next week is conference week and that means companies should have big news for investors. Here’s how to play it.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.